Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Has Average Price Target of $366.67

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) have been given an average recommendation of “Hold” by the five research firms that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $366.67.

A number of research firms have issued reports on BIO. Weiss Ratings upgraded Bio-Rad Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 9th. Citigroup lifted their target price on Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada lifted their price target on shares of Bio-Rad Laboratories from $390.00 to $440.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Wells Fargo & Company increased their price target on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Finally, Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th.

Read Our Latest Stock Analysis on BIO

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $358.17 on Friday. The stock has a market cap of $9.63 billion, a PE ratio of 9.43 and a beta of 1.06. Bio-Rad Laboratories has a one year low of $236.73 and a one year high of $396.23. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.18 and a quick ratio of 2.37. The stock has a 50-day moving average of $371.65 and a 200-day moving average of $319.11.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.23 by $0.42. Bio-Rad Laboratories had a return on equity of 3.58% and a net margin of 39.45%. The firm had revenue of $656.40 million during the quarter, compared to analysts’ expectations of $649.94 million. During the same period in the previous year, the firm earned $2.26 earnings per share. The company’s revenue was up .5% on a year-over-year basis. As a group, sell-side analysts expect that Bio-Rad Laboratories will post 9.71 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Jonathan P. Divincenzo sold 919 shares of the company’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $390.47, for a total value of $358,841.93. Following the completion of the transaction, the chief operating officer directly owned 1,962 shares in the company, valued at approximately $766,102.14. The trade was a 31.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Courtney C. Enloe sold 902 shares of the company’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $386.17, for a total transaction of $348,325.34. Following the completion of the sale, the executive vice president directly owned 750 shares of the company’s stock, valued at $289,627.50. This trade represents a 54.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,221 shares of company stock worth $1,247,049. Insiders own 30.34% of the company’s stock.

Institutional Trading of Bio-Rad Laboratories

A number of hedge funds and other institutional investors have recently bought and sold shares of BIO. Assenagon Asset Management S.A. grew its holdings in Bio-Rad Laboratories by 57.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 233,227 shares of the medical research company’s stock valued at $68,478,000 after buying an additional 85,393 shares in the last quarter. Hosking Partners LLP increased its holdings in Bio-Rad Laboratories by 1.1% during the third quarter. Hosking Partners LLP now owns 95,472 shares of the medical research company’s stock valued at $36,061,000 after buying an additional 1,042 shares during the period. Hound Partners LLC boosted its position in shares of Bio-Rad Laboratories by 125.9% in the 1st quarter. Hound Partners LLC now owns 97,724 shares of the medical research company’s stock worth $27,241,000 after purchasing an additional 54,456 shares in the last quarter. Marshall Wace LLP lifted its position in Bio-Rad Laboratories by 258.2% during the 3rd quarter. Marshall Wace LLP now owns 67,994 shares of the medical research company’s stock worth $25,682,000 after acquiring an additional 49,014 shares during the period. Finally, Portolan Capital Management LLC boosted its holdings in shares of Bio-Rad Laboratories by 30.9% in the 3rd quarter. Portolan Capital Management LLC now owns 55,797 shares of the medical research company’s stock valued at $21,075,000 after acquiring an additional 13,177 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

(Get Free Report)

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.

Read More

Analyst Recommendations for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.